hit counter
Arbutus Biopharma Corporation (ABUS) Stock News Sentiment & Price - Sentifly
ABUS - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Arbutus Biopharma Corporation (ABUS)

Canada
Biotechnology
NASDAQ
ABUS Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ABUS Latest news
GlobeNewsWire
Neutral
Arbutus Biopharma Appoints Tram Tran, M.D. to its Board of Directors
2021-11-11 07:30

WARMINSTER, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different modes of action to provide a cure for people with chronic hepatitis B virus (HBV) infection and to treat coronaviruses (including COVID-19), today announced that Tram Tran, M.D. has been appointed to the Arbutus Board of Directors effective immediately. Dr. Tran is a renowned liver and viral specialist with over 20 years of academic and industry experience as a physician scientist.

GlobeNewsWire
Neutral
Arbutus Announces New Data on AB-729 in Late Breaker Poster Presentation at AASLD - The Liver Meeting®
2021-11-10 16:30

Arbutus' Lead Compound AB-729 Continues to be Safe and Effective at Reducing HBsAg in Patients with Chronic Hepatitis B

GlobeNewsWire
Neutral
Arbutus to Participate at Jefferies London Healthcare Conference
2021-11-10 07:30

WARMINSTER, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different modes of action to provide a cure for people with chronic hepatitis B virus (HBV) infection and to treat coronaviruses (including COVID-19), today announced that the Company will participate in a virtual fireside chat at the Jefferies London Healthcare Conference.

Seeking Alpha
Neutral
Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q3 2021 Results - Earnings Call Transcript
2021-11-04 14:15

Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q3 2021 Results - Earnings Call Transcript

Zacks Investment Research
Positive
Arbutus Biopharma (ABUS) Reports Q3 Loss, Tops Revenue Estimates
2021-11-04 09:57

Arbutus (ABUS) delivered earnings and revenue surprises of 0.00% and 41.53%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire
Neutral
Arbutus Reports Third Quarter 2021 Financial Results and Provides Corporate Update
2021-11-04 07:30

On-track for multiple data readouts of AB-729 and AB-836 in Q4 2021

GlobeNewsWire
Neutral
Arbutus Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® 2021
2021-11-01 16:05

WARMINSTER, Pa., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different mechanisms of action to provide a cure for people with chronic hepatitis B virus (HBV) infection and to treat coronaviruses (including COVID-19), today announced that the Company will be presenting data on the effects of its GalNAc-siRNA, AB-729, in chronic hepatitis B patients on nucleos(t)ide analogue therapy at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting ® 2021 – The Digital Experience™, taking place from November 12-15, 2021.

Zacks Investment Research
Negative
Will Arbutus Biopharma (ABUS) Report Negative Earnings Next Week? What You Should Know
2021-10-28 16:49

Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PennyStocks
Positive
5 Short Squeeze Penny Stocks To Watch For November 2021
2021-10-26 11:16

Are these penny stocks ready to short squeeze? The post 5 Short Squeeze Penny Stocks To Watch For November 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

GlobeNewsWire
Neutral
Arbutus to Report Third Quarter 2021 Financial Results and Provide Corporate Update
2021-10-21 07:30

WARMINSTER, Pa., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different mechanisms of action to provide a cure for people with chronic hepatitis B virus (HBV) infection and to treat coronaviruses (including COVID-19), today announced that it has scheduled its third quarter 2021 financial results and corporate update for Thursday, November 4, 2021. The schedule for the press release and conference call/webcast are as follows:

Loading more news...